Biomolecules & Therapeutics

The Korean Society of Applied Pharmacology (한국응용약물학회)
권호 표지
DOI QR코드

DOI QR Code

Targeting Multidrug Resistance with Small Molecules for Cancer Therapy

  • Xia, Yan (Department of Medical Biotechnology, College of Life Science and Biotechnology, Dongguk University-Seoul) ;
  • Lee, Kyeong (Department of Medical Biotechnology, College of Life Science and Biotechnology, Dongguk University-Seoul)
  • Received : 2010.07.12
  • Accepted : 2010.10.03
  • Published : 2010.10.31
Download PDF
⟨ Previous Next ⟩

Abstract

Conventional cancer chemotherapy is seriously limited by tumor cells exhibiting multidrug resistance (MDR), which is caused by changes in the levels or activity of membrane transporters that mediate energy-dependent drug efflux and of proteins that affect drug metabolism and/or drug action. Cancer scientists and oncologists have worked together for some time to understand anticancer drug resistance and develop pharmacological strategies to overcome such resistance. Much focus has been on the reversal of the MDR phenotype by inhibition of ATP-binding cassette (ABC) drug transporters. ABC transporters are a family of transporter proteins that mediate drug resistance and low drug bioavailability by pumping various drugs out of cells at the expense of ATP hydrolysis. Many inhibitors of MDR transporters have been identified, and though some are currently undergoing clinical trials, none are in clinical use. Herein, we briefly review the status of MDR in human cancer, explore the pathways of MDR in chemotherapy, and outline recent advances in the design and development of MDR modulators.

Keywords

References

  1. Abolhoda, A., Wilson, A. E., Ross, H., Denenberg, R. V., Burt,M. and Scotto, K. W. (1999). Rapid activation of MDR1 geneexpression in human metastatic sarcoma after in vivoexposure to doxorubicin. Clin. Cancer Res. 5, 3352-3356.
  2. Almquist, K. C., Loe, D. W., Hipfner, D. R., Mackie, J. E., Cole,S. P. and Deeley, R. G. (1995). Characterization of the M190 000 multidrug resistance protein (MRP) in drug selectedand transfected human tumor cell. Cancer Res. 55, 102-110.
  3. Ambudkar, S. V., Dey, S., Hrycyna, C. A., Ramachandra, M.,Pastan, I. and Gottesman, M. M. (1999). Biochemical, cellularand pharmacological aspects of the multidrug transporter.Annu. Rev. Pharmacol. Toxicol. 34, 361-398.
  4. Anderle, P., Huang, Y. and Sadee, W. (2004). Intestinal membranetransport of drugs and nutrients: Genomics of membranetransporters using expression microarrays. Eur. J.Pharm. Sci. 21, 17-24. https://doi.org/10.1016/S0928-0987(03)00169-6
  5. Beck, J., Gekeler, V., Handgretinger, R. and Niethammer, D.(1994). PCR gene expression analysis of multidrug resistanceassociated genes in primary and relapsed stateleukemias: comparison of mdrl, mrp, topoisomerase IIa,topoisomerase IIb and cyclin A mRNA levels. Proc. Am.Assoc. Cancer Res. 35, 337.
  6. Benet, L. Z. and Cummins, C. L. (2001). The drug efflux- metabolismalliance: biochemical aspects. Adv. Drug Deliv. Rev.50(Suppl 1), S3-S11. https://doi.org/10.1016/S0169-409X(01)00178-8
  7. Borst, P., Evers, R., Kool, M. and Wijnholds, J. (2000). A familyof drug transporters: the multidrug resistance-associatedproteins. J. Natl. Cancer Inst. 92, 1295-302. https://doi.org/10.1093/jnci/92.16.1295
  8. Borst, P., Kool, M. and Evers, R. (1997). Do cMOAT (MRP2),other MRP homologues, and LRP play a role in MDR.Cancer Biol. 8, 205-213. https://doi.org/10.1006/scbi.1997.0071
  9. Broxterman, H. J., Kuiper, C. M., Schuurhuis, G. J., Ossen koppele, G. J., Feller, N., Scheper, R. J., Lankelma, J. andPinedo, H. M. (1994). Analysis of P-glycoprotein (P-gp) andnon-P-gp multidrug resistance in acute myeloid leukemia.Proc. Am. Assoc. Cancer Res. 35, 348.
  10. Chearwae, W., Wu, C. P., Chu, H. Y., Lee, T. R., Ambudkar, S.V. and Limtrakul, P. (2006). Curcuminoids purified fromtumeric powder modulate the function of human multidrugresistance protein 1 (ABCC1). Cancer Chemother. Pharmacol.57, 376-388. https://doi.org/10.1007/s00280-005-0052-1
  11. Choi, C. H. (2005). ABC transporters as multidrug resistancemechanisms and the development of chemosensitizers fortheir reversal. Cancer Cell Int. 5, 30. https://doi.org/10.1186/1475-2867-5-30
  12. Coburger, C., Wollmann, J., Baumert, C., Krug, M., Molna´r, J.,Lage, H. and Hilgeroth, A. (2008). Novel insight in structureactivityrelationship and bioanalysis of P-Glycoprotein targetinghighly potent tetrakishydroxymethyl substituted 3,9-Diazatetraasteranes. J. Med. Chem. 51, 5871-5874. https://doi.org/10.1021/jm800480y
  13. Colabufo, N. A., Berardi, F., Cantore, M., Perrone, M. G., Contino,M., Inglese, C., Niso, M., Perrone, R., Azzariti, A.,Simone, G. M., Porcelli, L. and Paradiso, A. (2008a). SmallP-gp modulating molecules: SAR studies on tetrahydroisoquinolinederivatives. Bioorg. Med. Chem. 16, 362-373.
  14. Colabufo, N. A., Berardi, F., Perrone, R., Rapposelli, S., Digiacomo,M., Vanni, M. and Balsamo, A. (2008b). Synthesisand biological evaluation of (Hetero) arylmethyloxy- and arylmethylamine-phenyl derivatives as potent P-glycoproteinmodulating agents. J. Med. Chem. 51, 1415-1422. https://doi.org/10.1021/jm701267q
  15. Colabufo, N. A., Berardi, F., Perrone, R., Rapposelli, S., Digiacomo,M., Vanni, M. and Balsamo, A. (2008c). 2-[(3-Methoxyphenylethyl)phenoxy]-based ABCB1 Inhibitors: effect ofdifferent basic side-chains on their biological properties. J.Med. Chem. 51, 7602-7613. https://doi.org/10.1021/jm800928j
  16. Dantzig, A. H., Shepard, R. L., Law, K. L., Tabas, L., Pratt, S.,Gillespie, J. S., Binkley, S. N., Kuhfeld, M. T., Starling, J. J.and Wrighton, S. A. (1999). Selectivity of the multidrug resistancemodulator, LY335979, for P-glycoprotein and effect oncytochrome P-450 activities. J. Pharmacol. Exp. Ther. 290,854-862.
  17. Das, U., Molnár, J., Bará th, Z., Bata, Z. and Dimmock, J. R. (2008).1-[4-(2-Aminoethoxy)phenylcarbonyl]-3,5-bis (benzylidene)-4-oxopiperidines: a novel series of highly potent revertants ofP-glycoprotein associated multidrug resistance. Bioorg.Med. Chem. Lett. 18, 3484-3487. https://doi.org/10.1016/j.bmcl.2008.05.034
  18. Dean, M., Rzhetsky, A. and Allikmets, R. (2001). The humanATP-binding cassette (ABC) transporter superfamily. GenomeRes. 11, 1156-1166. https://doi.org/10.1101/gr.GR-1649R
  19. Demant, E. J., Sehested, M. and Jensen, P. B. (1990). A modelfor computer simulation of P-glycoprotein and transmembranedelta pH-mediated anthracycline transport in multidrug resistanttumor cells. Biochim. Biophys. Acta. 1055, 117-125. https://doi.org/10.1016/0167-4889(90)90111-P
  20. Efferth, T. (2001). The human ATP-binding cassette transportergenes: from the bench to the bedside. Curr. Mol. Med. 1,45-65. https://doi.org/10.2174/1566524013364194
  21. Fan, D., Beltran, P. J. and O’Brien, C. A. (1994). Reversal ofmultidrug resistance. In Reversal of Multidrug Resistance inCancer (J. A. Kellen, Ed.), pp. 93-124. CRC Press, BocaRaton, FL.
  22. Fong, W. F., Shen, X. L., Globisch, C., Wiese, M., Chen, G. Y.,Zhu, G. Y., Yu, Z. L., Tse, A. K. W. and Hue, Y. J. (2008).Methoxylation of 3’,4’-aromatic side chains improvesP-glycoprotein inhibitory and multidrug resistance reversalactivities of 7,8-pyranocoumarin against cancer cells. Bioorg.Med. Chem. 16, 3694-3703. https://doi.org/10.1016/j.bmc.2008.02.029
  23. Ford, J. M. and Hait, W. N. (1990). Pharmacology of drugs thatalter multidrug resistance in cancer. Pharmacol. Rev. 42,155-199.
  24. Garcia, M., Jemal, A., Ward, E. M., Center, M. M., Hao, Y.,Siegel, R. L. and Thun, M. J. (2007). Global Cancer Factsand Figures 2007. American Cancer Society, Atlanta, GA.
  25. Gottesman, M. M. (2002). Mechanisms of cancer drug resistance.Annu. Rev. Med. 53, 615-627. https://doi.org/10.1146/annurev.med.53.082901.103929
  26. Gottesman, M. M., Fojo, T. and Bates, S. E. (2002). Multidrugresistance in cancer: role of ATP-dependent transporters.Nature Reviews Cancer 2, 48-58. https://doi.org/10.1038/nrc706
  27. Gottesman, M. M. and Pastan, I. (1996). Drug resistance:alterations in drug uptake or extrusion. In Encyclopedia ofCancer (J. R. Bertino, Ed.) pp. 549-559. Academic, SanDiego, CA.
  28. Gruber, A., Bjorkholm, M., Brinch, L., Evensen, S., Gustavsson,B., Hedenus, M., Juliusson, G., Löfvenberg, E., Nesthus, I.,Simonsson, B., Sjo, M., Stenke, L., Tangen, J. M., Tidefelt,U., Udén, A. M., Paul, C. and Liliemark, J. (2003). A phaseI/II study of the MDR modulator Valspodar (PSC 833)combined with daunorubicin and cytarabine in patients withrelapsed and primary refractory acute myeloid leukemia.Leuk. Res. 27, 323-328. https://doi.org/10.1016/S0145-2126(02)00181-9
  29. Hacker, H. G., de la Haye, A., Sterz, K., Schnakenburg, G.,Wiese, M. and Gutschow, M. (2009a). Analogs of a4-aminothieno[2,3-d]pyrimidine lead (QB13) as modulatorsof P-glycoprotein substrate specificity. Bioorg. Med. Chem.Lett. 19, 6102-6105. https://doi.org/10.1016/j.bmcl.2009.09.023
  30. Hacker, H. G., Leyers, S., Wiendlocha, J., Gutschow, M. andWiese, M. (2009b). Aromatic 2-(Thio)ureidocarboxylic acidsas a new family of modulators of multidrug resistanceassociatedprotein 1: synthesis, biological evaluation, andstructure-activity relationships. J. Med. Chem. 52, 4586-4595. https://doi.org/10.1021/jm900688v
  31. Hao, X. Y., Widersten, M., Ridderstrom, M., Hellman, U. andMannervik, B. (1994). Covariation of glutathione transferaseexpression and cytostatic drug resistance in HeLa cells:establishment of class Mu glutathione transferase M3-3 asthe dominating isoenzyme. Biochem. J. 297, 59-67. https://doi.org/10.1042/bj2970059
  32. Henrich, C. J., Bokesch, H. R., Dean, M., Bates, S. E., Robey,R. W., Goncharova, E. I., Wilson, J. A. and McMahon, J. B.(2006). A high-throughput cell-based assay for inhibitors ofABCG2 activity. J. Biomol. Screen 11, 176-183. https://doi.org/10.1177/1087057105284576
  33. Jin, J., Shahi, S., Kang, H. K., Van Veen, H. W. and Fan, T. P.(2006). Metabolism of ginsenosides as novel BCRP inhibitors.Biochem. Biophys. Res. Commun. 345, 1308-1314. https://doi.org/10.1016/j.bbrc.2006.04.152
  34. Jin, J., Wang, F. P., Wei, H. and Liu, G. (2005). Reversal ofmultidrug resistance of cancer through inhibition of Pglycoproteinby 5-bromotetrandrine. Cancer Chemother.Pharmacol. 55, 179-188. https://doi.org/10.1007/s00280-004-0868-0
  35. Katayama, K., Masuyama, K., Yoshioka, S., Hasegawa, H.,Mitsuhashi, J. and Sugimoto, Y. (2007). Flavonoids inhibitbreast cancer resistance protein-mediated drug resistance:transporter specificity and structure-activity relationship.Cancer Chemother. Pharmacol. 60, 789-797. https://doi.org/10.1007/s00280-007-0426-7
  36. Kellen, J. A. (2003). The reversal of multidrug resistance: anupdate. J. Exp. Ther. Oncol. 3, 5-13. https://doi.org/10.1046/j.1359-4117.2003.01067.x
  37. Kim, D. H., Park, J. Y., Sohn, S. K., Lee, N. Y., Baek, J. H., Jeon, S. B., Kim, J. G., Suh, J. S., Do, Y. R. and Lee, K. B.(2006). Multidrug resistance-1 gene polymorphismsassociated with treatment outcomes in de novo acutemyeloid leukemia. Int. J. Cancer 118, 2195-2201. https://doi.org/10.1002/ijc.21666
  38. Kim, R. B., Wandel, C., Leake, B., Cvetkovic, M., Fromm, M. F.,Dempsey, P. J., Roden, M. M., Belas, F., Chaudhary, A. K.,Roden, D. M., Wood, A. J. and Wilkinson, G. R. (1999).Interrelationship between substrates and inhibitors of humanCYP3A and P-glycoprotein. Pharm. Res. 16, 408-414. https://doi.org/10.1023/A:1018877803319
  39. Krishna, R. and Mayer, L. D. (2000). Multidrug resistance(MDR) in cancer. Mechanisms, reversal using modulators ofMDR and the role of MDR modulators in influencing thepharmacokinetics of anticancer drugs. Eur. J. Pharm. Sci.11, 265-283. https://doi.org/10.1016/S0928-0987(00)00114-7
  40. Krug, M., Voigt, B., Baumert, C., Lupken, R., Molnar, J. andHilgeroth, A. (2010). First biological evaluation of developed3-benzyloxyfluorenes as novel class of MDR modulators.Eur. J. Med. Chem. 45, 2683-2688 https://doi.org/10.1016/j.ejmech.2010.02.024
  41. Kuhnle, M., Egger, M., Muller, C., Mahringer, A., Bernhardt,G., Fricker,G., Konig, B. and Buschauer, A. (2009). Potentand selective inhibitors of breast cancer resistance protein(ABCG2) derived from the P-Glycoprotein (ABCB1)modulator tariquidar. J. Med. Chem. 52, 1190-1197. https://doi.org/10.1021/jm8013822
  42. Leonard, G. D., Fojo, T. and Bates, S. E. (2003). The role ofABC transporters in clinical practice. Oncologist 8, 411-424. https://doi.org/10.1634/theoncologist.8-5-411
  43. Li, Y., Zhang, H. B. and Huang, W. L. (2008). Design andsynthesis of tetrahydroisoquinoline derivatives as potentialmultidrug resistance reversal agents in cancer. Bioorg. Med.Chem. Lett. 18, 3652-3655. https://doi.org/10.1016/j.bmcl.2008.04.082
  44. Limtrakul, P. (2007). Curcumin as chemosensitizer. Adv. Exp.Med. Biol. 595, 269-300. https://doi.org/10.1007/978-0-387-46401-5_12
  45. Limtrakul, P., Chearwae, W., Shukla, S., Phisalphong, C. andAmbudkar, S. V. (2007a). Modulation of function of threeABC transporters, P-glycoprotein (ABCB1), mitoxanthroneresistance protein (ABCG2) and multidrug resistance protein1 (ABCC1) by tetrahydrocurcumin, a major metabolite ofcurcumin. Mol. Cell Biochem. 296, 85-95. https://doi.org/10.1007/s11010-006-9302-8
  46. Limtrakul, P., Siwanon, S., Yodkeeree, S. and Duangrat, C.(2007b). Effect of Stemona curtisii root extract onP-glycoprotein and MRP-1 function in multidrug-resistantcancer cells. Phytomedicine 14, 381-389. https://doi.org/10.1016/j.phymed.2007.03.006
  47. Liscovitch, M. and Lavie, Y. (2002). Cancer multidrug resistance:a review of recent drug discovery research. Drugs 5,349-355.
  48. Liu, D. F., Li, Y. P., Ou, T. M., Huang, S. L., Gu, L. Q., Huang, M.and Huang, Z. S. (2009). Synthesis and antimultidrugresistance evaluation of icariin and its derivatives. Bioorg.Med. Chem. Lett. 19, 4237-4240. https://doi.org/10.1016/j.bmcl.2009.05.103
  49. Longley, D. B. and Johnston, P. G. (2005). Molecular mechanismsof drug resistance. J. Pathol. 205, 275-292. https://doi.org/10.1002/path.1706
  50. Martelli, C., Coronnello, M., Dei, S., Manetti, D., Orlandi, F.,Scapecchi, S., Romanelli, M. N., Salerno, M., Mini, E. andTeodori, E. (2010). Structure-activity relationships studies ina series of N,N-Bis(alkanol)amine aryl esters as P-Glycoprotein(Pgp) dependent multidrug resistance (MDR)inhibitors. J. Med. Chem. 53, 1755-1762. https://doi.org/10.1021/jm9016174
  51. Min, K. H., Xia, Y., Kim, E. K., Jin, Y. L., Kaur, N., Kim, E. S.,Kim, D. K., Jung, H. Y., Choi, Y., Park, M. K., Min, Y. K., Lee,K. and Lee, K. (2009). A novel class of highly potentmultidrug resistance reversal agents: Disubstituted adamantylderivatives. Bioorg. Med. Chem. Lett. 19, 5376-5379. https://doi.org/10.1016/j.bmcl.2009.07.127
  52. Nakamura, M., Abe, Y., Katoh, Y., Oshika, Y., Hatanaka, H.,Tsuchida, T., Yamazaki, H., Kijima, H., Inoue, H. andUeyama, Y. (2000). A case of pulmonary adencarcinomawith overexpression of multidrug resistance associatedprotein and p53 aberration. Anticancer Res. 20, 1921-1925.
  53. Newman, M. J., Rodarte, J. C., Benbatoul, K. D., Romano, S. J.,Zhang, C., Krane, S., Moran, E. J., Uyeda, R. T., Dixon, R.,Guns, E. S. and Mayer, L. D. (2000). Discovery and characterizationof OC144-093, a novel inhibitor of P-glycoproteinmediatedmultidrug resistance. Cancer Res. 60, 2964-2972.
  54. Pluen, A., Boucher, Y., Ramanujan, S., McKee, T. D., Gohongi,T., Tomaso, E., Brown, E. B., Izumi, Y., Campbell, R. B.,Berk, D. A. and Jain, R. K. (2001). Role of tumor-host interactionsin interstitial diffusion of macromolecules: cranial vs.subcutaneous tumors. Proc. Natl. Acad. Sci. 98, 4628-4633. https://doi.org/10.1073/pnas.081626898
  55. Polgar, O. and Bates, S. E. (2004). ABC transporters in thebalance: is there a role in multidrug resistance? Biochem.Soc. Trans. 33, 241-245. https://doi.org/10.1042/BST0330241
  56. Raad, I., Terreux, R., Richomme, P., Matera, E. L., Dumontet,C., Raynaud, J. and Guilet, D. (2006). Structure- activityrelationship of natural and synthetic coumarins inhibiting themultidrug transporter P-glycoprotein. Bioorg. Med. Chem.14, 6979-6987. https://doi.org/10.1016/j.bmc.2006.06.026
  57. Romiti, N., Pellati, F., Nieri, P., Benvenuti, S., Adinolfi, B. andChieli, E. (2008). P-glycoprotein inhibitory activity of lipophilicconstituents of Echinacea pallida roots in a human proximaltubular cell lines. Planta Med. 74, 264-266. https://doi.org/10.1055/s-2008-1034308
  58. Rowinsky, E. K., Smith, L., Wang, Y. M., Chaturvedi, P.,Villalona, M., Campbell, E., Aylesworth, C., Eckhardt, S. G.,Hammond, L., Kraynak, M., Drengler, R., Stephenson, J. J.,Harding, M. W. and Von Hoff, D. D. (1998). Phase I andpharmacokinetic study of paclitaxel in combination withbiricodar, a novel agent that reverses multidrug resistanceconferred by overexpression of both MDR1 and MRP. J.Clin. Oncol. 16, 2964-2976. https://doi.org/10.1200/JCO.1998.16.9.2964
  59. Rubio, G. J., Pinedo, H. M., Gazdar, A. F., Van Ark-Otte, J. andGiaccone, G. (1994). MRP gene assessment in humancancer, normal lung, and lung cancer cell lines. Proc. Am.Assoc. Cancer Res. 35, 206.
  60. Shukla, S., Wu, C. P., and Ambudkar, S. V. (2008). Developmentof inhibitors of ATP-binding cassette drug transporters -present status and challenges. Expert Opin. Drug Metab.Toxicol. 4, 205-223. https://doi.org/10.1517/17425255.4.2.205
  61. Skupien, K., Kostrzewa-Nowak, D., Oszmianski, J. and Tarasiuk,J. (2008). In vitro antileukemia activity of extracts fromchokeberry (Aronia melanocarpa [Michx] Elliot) and mulberry(Morus alba L.) leaves against sensitive and multidrugresistant HL60 cells. Phytother. Res. 22, 689-694. https://doi.org/10.1002/ptr.2411
  62. Takahashi, K., Kimura, Y., Nagata, K., Yamamoto, A., Matsuo,M. and Ueda, K. (2005). ABC proteins: key molecules forlipid homeostasis. Med. Mol. Morphol. 38, 2-12. https://doi.org/10.1007/s00795-004-0278-8
  63. Theis, J. G., Chan, H. S., Greenberg, M. L., Malkin, D., Karaskov,V., Moncica, I., Koren, G. and Doyle, J. (2000). Assessmentof systemic toxicity in children receiving chemotherapy withcyclosporine for sarcoma. Med. Pediatr. Oncol. 34, 242-249. https://doi.org/10.1002/(SICI)1096-911X(200004)34:4<242::AID-MPO2>3.0.CO;2-U
  64. Thomas, H. and Coley, H. M. (2005). Overcoming multidrugresistance in cancer: an update on the clinical strategy ofinhibiting p-glycoprotein. Cancer Control 10, 159-165.
  65. Toppmeyer, D., Seidman, A. D., Pollak, M., Russell, C., Tkaczuk,K., Verma, S., Overmoyer, B., Garg, V., Ette, E., Harding, M.W. and Demetri, G. D. (2002). Safety and efficacy of the multidrug resistance inhibitor Incel (biricodar; VX-710) incombination with paclitaxel for advanced breast cancerrefractory to paclitaxel. Clin. Cancer Res. 8, 670-678.
  66. Van Zanden, J. J., De Mul, A., Wortelboer, H. M., Usta, M., vanBladeren, P. J., Ivonne, M. C., Rietjens, M., Nicole, H. andCnubben, P. (2005). Reversal of in vitro cellular MRP1 andMRP2 mediated vincristine resistance by the flavonoidmyricetin. Biochem. Pharmacol. 69, 1657-1665. https://doi.org/10.1016/j.bcp.2005.03.001
  67. Viale, M., Cordazzo, C., Cosimelli, B., de Totero, D.,Castagnola, P., Aiello, C., Severi, E., Petrillo, G., Cianfriglia,M. and Spinelli, D. (2009). Inhibition of MDR1 activity in vitroby a novel class of diltiazem analogues: toward newcandidates. J. Med. Chem. 52, 259-266. https://doi.org/10.1021/jm801195k
  68. Wada, M. (2006). Single nucleotide polymorphisms in ABCC2and ABCB1 genes and their clinical impact in physiology anddrug response. Cancer Letter 234, 40-50. https://doi.org/10.1016/j.canlet.2005.06.050
  69. Weiss, J., Sauer, A., Frank, A. and Unger, M. (2005). Extractsand kavalactones of Piper methysticum G. Forst (kava-kava)inhibit P-glycoprotein in vitro. Drug Metab. Dispos. 33,1580-1583. https://doi.org/10.1124/dmd.105.005892
  70. Wu, C. P., Calcagno, A. M., Hladky, S. B., Ambudkar, S. V. andBarrand, M. A. (2005). Modulatory effects of plant phenolson human multidrug-resistance proteins 1, 4 and 5 (ABCC1,4 and 5). FEBS J. 272, 4725-4740. https://doi.org/10.1111/j.1742-4658.2005.04888.x
  71. Xia, Y., Min, K. H. and Lee, K. (2009). Synthesis and BiologicalEvaluation of Decursin, Prantschimgin and Their Derivatives.Bull. Korean Chem. Soc. 30, 43-48. https://doi.org/10.5012/bkcs.2009.30.1.043
  72. Yu, S. T., Chen, T. M., Tseng, S. Y. and Chen, Y. H. (2007).Tryotanthrin inhibits MDR1 and reverses doxorubicin resistancein breast cancer cells. Biochem. Biophys. Res.Commun. 358, 79-84. https://doi.org/10.1016/j.bbrc.2007.04.107
  73. Zaman, G. J. R., Versantvoort, C. H. M., Smit, J. J. M., Eijdems,E. W. H. M., De Haas, M., Smith, A. J., Broxterman, H. J.,Mulder, N. H., De Vries, E. G. E., Baas, F. and Borst, P.(1993). Analysis of the expression of MRP, the gene for anew putative transmembrane drug transporter, in humanmultidrug resistant lung cancer cell lines. Cancer Res. 53,1747-1750.

Cited by

  1. Synthesis and Bioactivity of Novel Adamantyl Derivatives as Potent MDR Reversal Agents vol.32, pp.12, 2011, https://doi.org/10.5012/bkcs.2011.32.12.4444
  2. Indirect modulation of sensitivity to 5-fluorouracil by microRNA-96 in human colorectal cancer cells vol.38, pp.2, 2015, https://doi.org/10.1007/s12272-014-0528-9
  3. The distribution and retention of paclitaxel and doxorubicin in multicellular layer cultures vol.27, pp.4, 2012, https://doi.org/10.3892/or.2012.1650
  4. Structure–Activity Relationship Study of Permethyl Ningalin B Analogues as P-Glycoprotein Chemosensitizers vol.56, pp.22, 2013, https://doi.org/10.1021/jm400930e
  5. Emerging Therapeutics to Overcome Chemoresistance in Epithelial Ovarian Cancer: A Mini-Review vol.18, pp.10, 2017, https://doi.org/10.3390/ijms18102171
  6. Tumour Regression via Integrative Regulation of Neurological, Inflammatory, and Hypoxic Tumour Microenvironment vol.28, pp.2, 2020, https://doi.org/10.4062/biomolther.2019.135